Macimorelin acetate is under clinical development by Aeterna Zentaris and currently in Phase III for Growth Hormone Deficiency. According to GlobalData, Phase III drugs for Growth Hormone Deficiency have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Macimorelin acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Macimorelin acetate overview

Macimorelin acetate (AEZS-130) is under development for the treatment cancer-induced cachexia, growth hormone deficiency and amyotrophic lateral sclerosis. The drug candidate is an oral secretagogue. It acts by targeting ghrelin and growth hormone (GH).

Aeterna Zentaris overview

Aeterna Zentaris is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of unmet medical needs. The company’s lead product, Macrilen (macimorelin), a ghrelin receptor agonist and the orally active small molecule is used for the treatment of patients with adult growth hormone deficiency (AGHD). The company has operations in the US, Canada, and Germany and has license agreements for its products in Ireland, China, the British Virgin Islands, Denmark, and other countries. Aeterna Zentaris is headquartered in Summerville, South Carolina, the US.

For a complete picture of Macimorelin acetate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.